Loading…
Employees: 983
Size AK Medical (1789.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $664M, the 687th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$4.70 on 6 Nov 2026.
Performance Over six months the shares fell 25.8%, against -9.9% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue grew 16.1% over the last twelve months (peer median +9.5%); the operating margin is 26.4% (peer median 10.2%).
Valuation It trades at 10.8× forward earnings against a peer median of 22.6× (2nd cheapest of 16).
Price implies For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -18 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 14.7 points above its cost of capital (6.2% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$1.73B | HK$1.61B | HK$1.46B | HK$1.21B | HK$1.22B |
| Revenue growth | — | +10% | +21% | -1% | — |
| Gross profit | HK$1.09B | HK$948M | HK$854M | HK$729M | HK$726M |
| EBITDA | HK$582M | HK$489M | HK$413M | HK$305M | HK$358M |
| Net income | HK$420M | HK$368M | HK$297M | HK$201M | HK$238M |
| Free cash flow | HK$369M | HK$352M | HK$341M | -HK$140M | HK$170M |
| Capital expenditure | HK$89.4M | HK$134M | HK$176M | HK$217M | HK$138M |
| Total debt | n/a | HK$161M | HK$138M | HK$119M | HK$43.5M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1789.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.7% | -2.0% | 9th highest of 21 |
| 6-month return | -25.8% | -9.9% | 6th lowest of 21 |
| Distance from 52-week high | -34.3% | -32.9% | 11th highest of 21 |
| Revenue growth (TTM) | +16.1% | +9.5% | 9th highest of 21 |
| Operating margin | 26.4% | 10.2% | 5th highest of 21 |
| Forward P/E | 10.8× | 22.6× | 2nd cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | -11.4% | 8.1% | least demanding of 14 |
| Growth delivered (Del g) | +6.7% | +14.2% | 5th lowest of 14 |
| Hurdle (Req g minus delivered) | -18.1 pp | -9.2 pp | 4th least demanding of 14 |
| ROIC minus cost of capital | +14.7 pp | -1.9 pp | 6th highest of 21 |
| EV / EBITDA | 6.6× | 17.1× | cheapest of 8 |
| Net debt / EBITDA | -2.3× | -0.6× | least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| AK Medical 1789.HK | Hong Kong | $664M | -26% | +16% | 26% | 10.8× | -11.4% | +6.7% |
| Beijing Chunlizhengda Medical Instruments 1858.HK | Hong Kong | $671M | -27% | -9% | 31% | 9.2× | -8.0% | +1.5% |
| Cowealth Medical China 603122.SS | China | $648M | -28% | -18% | -5% | n/a | n/a | n/a |
| Jiangsu Hanvo Safety Product 300952.SZ | China | $681M | -21% | +6% | 8% | 47.6× | n/a | n/a |
| Japan Lifeline 7575.T | Japan | $685M | +16% | +6% | 19% | 14.1× | -9.7% | +2.9% |
| SunMax Biotechnology 4728.TWO | Taiwan | $643M | +1% | +12% | 50% | n/a | -0.7% | +18.8% |
| Xvivo Perfusion XVIVO.ST | Sweden | $635M | -29% | +18% | 12% | 54.2× | 35.7% | +35.2% |
| Shanghai Kinetic Medical 300326.SZ | China | $698M | -7% | -28% | 17% | 27.4× | 8.1% | -1.9% |
| Shanghai Sanyou Medical 688085.SS | China | $700M | -21% | +15% | 4% | 50.9× | 29.1% | +6.8% |
| Pacific Biosciences of California PACB | United States | $701M | +60% | +2% | -102% | n/a | n/a | n/a |
| Livsmed 491000.KS | South Korea | $706M | -47% | +89% | -59% | n/a | n/a | n/a |
| Synektik SNT.WA | Poland | $713M | +16% | +50% | 24% | 11.8× | 0.1% | +40.3% |
| Hangzhou AGS MedTech 688581.SS | China | $617M | -16% | -18% | 33% | 19.8× | 1.7% | +27.8% |
| Mesa Laboratories MLAB | United States | $718M | +23% | +3% | 9% | 12.6× | 21.1% | +13.2% |
| SWS Hemodialysis Care 688410.SS | China | $723M | -12% | +31% | 19% | 24.1× | 16.7% | +25.9% |
| Ningbo David Medical Device 300314.SZ | China | $607M | +22% | +19% | 11% | 12.3× | n/a | n/a |
| Shenzhen Sunnypol Optoelectornics 002876.SZ | China | $728M | -8% | +29% | 5% | 41.8× | 11.1% | +14.2% |
| Wuhan Huakang Century Clean Technology 301235.SZ | China | $603M | -42% | +28% | 7% | 22.6× | n/a | n/a |
| QuidelOrtho QDEL | United States | $734M | -1% | -5% | -2% | 12.0× | n/a | n/a |
| Medistim MEDI.OL | Norway | $601M | +30% | +19% | 29% | 30.5× | -1.8% | +14.5% |
| Contec Medical Systems 300869.SZ | China | $600M | -23% | -2% | -16% | n/a | 17.3% | -19.8% |